New Zealand markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
209.24+0.25 (+0.12%)
At close: 4:00PM EDT
208.82 -0.42 (-0.20%)
After hours: 06:14PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close208.99
Open209.70
Bid208.56 x 800
Ask209.98 x 1000
Day's range208.53 - 210.50
52-week range200.47 - 276.69
Volume1,349,344
Avg. volume2,551,457
Market cap118.817B
Beta (5Y monthly)0.68
PE ratio (TTM)21.22
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield7.04 (3.36%)
Ex-dividend date16 Aug 2021
1y target estN/A
All
News
  • GlobeNewswire

    FIVE PRIME ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FPRX and Encourages Investors to Contact the Firm

    NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Five Prime Therapeutics, Inc. (NASDAQ: FPRX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Amgen Inc. (NASDAQ: AMGN). Click here to learn more and participate in the action. On March 4, 2021, Five Prime announced that it had signed an agreement to be acquired by Amgen for approximately $1.9 billion. Pursuant to the merger agreement, Five Prime stockholders will receive $38 in cash for each share of Five Prime common stock owned. The deal is scheduled to close in the second quarter of 2021. Bragar Eagel & Squire is concerned that Five Prime’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Five Prime’s stockholders. If you own shares of Five Prime and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at investigations@bespc.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information:Bragar Eagel & Squire, P.C.Melissa Fortunato, Esq.Alexandra Raymond, Esq.investigations@bespc.comwww.bespc.com

  • Business Wire

    Amgen and McKesson Launch Strategic Agreement to Advance Cancer Innovation in Communities

    McKesson and Amgen (NASDAQ:AMGN), one of the world’s leading biotechnology companies, have signed a strategic agreement to help improve cancer care in community oncology settings. Today, 1 in 5 cancer patients receives an Amgen medicine, while McKesson reaches 20% of U.S. cancer patients. This multi-year agreement bridges the power and reach of the two companies and will focus on reducing gaps in care by optimizing access to innovative precision medicine and immuno-oncology in the community setting.